Compare LFCR & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFCR | DHIL |
|---|---|---|
| Founded | 1986 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.0M | 319.2M |
| IPO Year | N/A | 1995 |
| Metric | LFCR | DHIL |
|---|---|---|
| Price | $7.74 | $115.15 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 160.7K | 28.2K |
| Earning Date | 01-02-2026 | 10-30-2025 |
| Dividend Yield | N/A | ★ 5.15% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.21 |
| Revenue | $128,867,000.00 | ★ $149,665,296.00 |
| Revenue This Year | $4.72 | N/A |
| Revenue Next Year | $10.97 | N/A |
| P/E Ratio | ★ N/A | $6.74 |
| Revenue Growth | 0.47 | ★ 2.65 |
| 52 Week Low | $4.76 | $114.46 |
| 52 Week High | $8.85 | $169.35 |
| Indicator | LFCR | DHIL |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 22.52 |
| Support Level | $7.28 | $115.61 |
| Resistance Level | $7.93 | $119.09 |
| Average True Range (ATR) | 0.34 | 2.57 |
| MACD | 0.01 | -0.94 |
| Stochastic Oscillator | 38.02 | 3.51 |
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.